Videos

Pharmaceutical companies have already begun developing these boosters, and Haydock said he expects to see some variant-specific vaccines available by mid-2021.

Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy.

Ryan Haumschild, PharmD, MS, MBA, provides insight on biosimilar adoption both in oncology and non-oncology practice settings.

Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.

As the FDA and CDC have paused use of the Johnson & Johnson COVID-19 vaccine in the United States, research is ongoing to understand whether cerebral venous sinus thrombosis (CVST) is directly linked to the vaccine.

The impact on biosimilar utilization in clinical practice caused by secondary patents of biologics and skinny labels of biosimilars is discussed.

Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.

Madeline Camejo, PharmD, and Estela Trimino, PharmD, BCPS, discuss the emerging role of the pharmacist on the front line of vaccine administration.

Health system pharmacists discuss challenges with the COVID-19 vaccine rollout, such as having multiple vaccine types and lot numbers on hand and appointment no-shows

Megan May, PharmD, BCOP, Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, share their thoughts on unmet needs in the management of neuroendocrine tumors.

The experts discuss measures taken by pharmacy to prevent waste of vaccine doses and the education provided to members of the medical staff.

Madeline Camejo, PharmD, MS, leads discussion on vaccination of health care workers and the strategies implemented at their institutions to accomplish this task.

Madeline Camejo, PharmD, MS, and Michael Epshteyn, PharmD, MSM, discuss pharmacy’s involvement in the COVID-19 vaccine rollout and training pharmacists to be vaccinators.

Tim Peterson, PharmD, BCOP, leads the discussion on immunogenicity testing and lot-to-lot variability, including the potential impact on the safety and efficacy of reference biologics and their biosimilars.

Patricia Stinchfield, the president-elect of National Foundation for Infectious Diseases, discusses the recommended framework for vaccine messaging for leaders across sectors.

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.

Hager Hanon, PharmD, RPh, senior pharmacist at Community Care Rx, discusses COVID-19 vaccination hesitancy among pregnant women and people with a history of anaphylaxis.

A discussion on what it means for a biosimilar to have “interchangeability” status and its potential impact on biosimilar adoption in clinical practice.

A panel of experts in neuroendocrine tumors review the challenges in the management of patients based on the site of the tumor.

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

With their content ranging from pharmacy references in pop culture to more clinical discussions of specific drugs, the Let's Pharmonize podcast hosts have learned to balance the rigors of school with their biweekly podcast.

Ted Karkus, CEO of ProPhase Labs, discusses the differences between saliva COVID-19 tests and nasal swab COVID-19 tests and their different uses in clinical practice.

Estela Trimino, PharmD, BCPS, leads a discussion on changes in barcoding practices to address infection control challenges caused by COVID-19.

Michael Epshteyn, PharmD, MSM, discusses some of the infection control challenges caused by COVID-19, such as the procurement of personal protective equipment (PPE).

Estela Trimino, PharmD, BCPS, discusses the use and impact of premixed IV solutions and drug reconstitution systems compared to compounded IV products.

Megan May, PharmD, BCOP, reviews the authorization process for treatment options for the management of NETs.

Michael Epshteyn, PharmD, MSM, shares benefits and challenges of in-house compounding of IV products at his organization and the technologies involved.

Ryan Haumschild, PharmD, MS, MBA, defines biosimilars in oncology and what distinguishes them from a reference biologic.

Russell Brewer, DrPH, a research associate professor at University of Chicago Medicine, discusses the value of the pharmacist in improving access and engagement in care for Black same-gender-loving men.